IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Digital Twins In Drug Discovery: A Virtual Human For Preclinical Testing

A COMPARATIVE REVIEW OF CONCEPT, APPLICATIONS, CHALLENGES, ETHICAL ISSUES AND FUTURE PROSPECTS IN DIGITAL TWIN TECHNOLOGY.

[1]Ananya R. Sangar, [2]Saniya S. Sanadi, [3]Afrin A. Naykawadi, [4]Rutuja S. Ravtale, [5]Gayatri G. Ganjave

[1234] Department of Pharmaceutical Chemistry, Ashokrao Mane College of Pharmacy, Peth Vadgaon / Shivaji University 416112, Maharasthra, India

[5] Department of Pharmaceutics ,Ashokrao Mane College of Pharmacy, PethVadgaon /Shivaji University 416112, Maharasthra, India

Abstract :- Virtual copies of biological systems, or digital twin technologies, are becoming a game-changing tool in preclinical testing and contemporary drug discovery. Digital twins simulate illness progression, drug metabolism, and therapeutic results prior to clinical trials by combining real-time patient data, computational modeling, and multi-scale physiological data. This makes it possible to forecast drug toxicity, efficacy, and customized dosing plans in silico. The technique creates "virtual humans" for precision medicine applications by bridging systems pharmacology, bioinformatics, and artificial intelligence[34171827]. Standardization, data interoperability, and ethical issues, however, continue to be major obstacles[5789]. The architecture of digital twins, their uses in PK/PD modeling, and potential future paths for regulatory adoption in drug development are all examined in this review[2621].

Keywords: drug development, precision medicine, digital twin, computational modeling, and in silico pharmacology.

Introduction

In order to assess the safety, effectiveness, and pharmacokinetic properties of potential drugs prior to clinical trials, preclinical testing is still an essential phase in the drug discovery process[2621]. Conventional preclinical methods, however, have a number of drawbacks, such as exorbitant expenses, protracted development periods, moral dilemmas surrounding animal experimentation, and notable discrepancies between animal models and human physiology[12]. The high incidence of drug candidate attrition during clinical development is frequently caused by these constraints.

In silico simulations and computational modeling have become potential methods in recent years to supplement and, in certain situations, partially replace conventional preclinical experiments[34171827]. Researchers can more effectively and economically forecast drug behavior, adjust dosing plans, and assess possible toxicities by using methods including molecular docking, physiologically based pharmacokinetic (PBPK) modeling, and systems pharmacology[2621].

Recently, the biomedical field has adopted the Digital Twin (DT) idea, which was first created for engineering and industrial applications[25]. Molecular, cellular, organ-level, and patient-specific data are all continuously integrated into a dynamic, virtual representation of a biological system, which is known as a DT[5]. As "virtual humans," DTs provide a platform for personalized medicine and predictive pharmacology in the context of drug development by simulating illness progression, drug metabolism, and therapeutic responses[2621].

With a focus on its conceptual architecture, real-world applications, benefits, and the moral and legal issues surrounding its use, this review aims to give a thorough overview of digital twin technology in drug design and preclinical testing[5789]. This study seeks to emphasize how DTs have the potential to revolutionize drug discovery in the future by showcasing current developments and ongoing studies.

Table.1 Difference between Digital Twin Approach and Traditional Preclinical Testing

Feature	Digital Twin Approach	Traditional Preclinical Testing
Cost	Lower	Higher
Ethical Concerns	Reduced animal use	Significant animal use
Prediction Accuracy	High (multi-scale integration)	Variable, model-dependent
Personalization	Yes (patient-specific simulations)	No
Speed of Development	Faster	Slower

2. Concept of Digital Twin Technology

In order to accurately depict physiological and pathological states, a digital twin (DT) is a dynamic, virtual representation of a biological system that continuously integrates and updates data from real-world sources[12].

To provide a prediction framework for comprehending disease progression, treatment response, and patient-specific therapy results, DTs are made to mimic the behavior of organs, tissues, cells, or even entire human systems in the biomedical context[2621].

A DT's architecture usually consists of three primary parts[34]:

1. **Physical Entity**: The actual patient or biological system that is used as a benchmark for validation and simulation.

2. **A virtual model**: is a computer representation that combines information on anatomy, physiology, molecules, and diseases. This approach makes it possible to simulate biological processes in a variety of settings. [34171827].

3. **Data Connection**: An ongoing feedback loop that adds real-time data from wearable technology, high-throughput omics analysis, clinical assessments, or experimental research to the virtual model. This guarantees that the DT will continue to be a precise and flexible representation of the physical entity[16].

Digital twins can be categorized according to their application and degree of detail:

1. **Organ-level twins**: Dedicated to certain organs, including the kidney, liver, or heart; frequently used for toxicity prediction and PK/PD modeling[2621].

2. **Cellular or molecular twins:** Target identification and drug mechanism studies are aided by cellular or molecular twins, which represent cellular networks or molecular pathways[34].

3. **Whole-body digital humans:** Virtual clinical trials and individualized treatment plans are made possible by whole-body digital people, which combine several organ and cellular models to offer a thorough simulation of human physiology and systemic reactions[56].

4. Digital twins are a potent tool for precision medicine and predictive pharmacology since the creation of these models depends on multi-scale data integration, computational biology, machine learning algorithms, and high-performance computing[34171827].

Table.2 Digital Twin (DT) synthesis across various biological scales

Scale Level	Primary Data Sources	Computational Models	DT Output/Function
Micro (Molecular/Cellular)	Genomics, Transcriptomics, Proteomics, Metabolomics (Multi-omics)	Cellular/Molecular Twins, Systems Biology Models	Target identification, Drug mechanism studies, Pathway simulation
Meso (Tissue/Organ)	Clinical Imaging (MRI, CT, PET scans), Histopathology	Organ-level twins (Heart, Liver, Kidney models)	Toxicity prediction (e.g., hepatotoxicity), PK/PD modeling at the organ level
Macro (Systemic/Whole-Body)	Real-time clinical data, Wearable devices, Biosensors, Clinical measurements	Whole-body digital humans, Physiologically Based Pharmacokinetic (PBPK) models	Virtual clinical trials, Personalized dosing, Simulation of systemic responses

3. Architecture and Data Integration

Digital twins (DTs) are used in drug discovery because of their architecture, which integrates data from various biological scales to accurately simulate intricate physiological and pathological processes[12]. A key component of this paradigm is multi-scale modeling, which predicts system-wide reactions to therapeutic interventions by combining dynamics at the molecular, cellular, tissue, and organ levels[34171827]. For preclinical and translational research, DTs offer a thorough grasp of disease processes and drug behavior by recording interactions at several scales[2621].

High-throughput genomes, transcriptomics, proteomics, metabolomics, and clinical imaging datasets including MRI, CT, and PET scans[34] are some of the many data sources for digital twins. In order to maintain the virtual model's reflection of the biological system's current physiological condition, several diverse datasets are constantly combined to update it[16]. The prediction power of the model is further improved by adding real-time clinical data from biosensors and wearable technology[16].

Artificial intelligence (AI) algorithms, machine learning frameworks, and systems biology models are among the computational tools that support DTs. These techniques allow for adaptive simulation of biological processes and dynamic model updating[34171827]. To facilitate dosage optimization and inter-individual variability assessment, for instance, Physiologically Based Pharmacokinetic (PBPK) models are a fundamental component for modeling drug absorption, distribution, metabolism, and excretion in virtual humans[2621].

Real-time data synchronization across many sources is made possible by the combination of cloud computing and the Internet of Medical Things (IoMT), enabling dispersed and scalable computation while preserving data security and integrity[56]. With the use of this computational infrastructure, DTs can reliably and effectively enable virtual clinical trials, customized medicine, and predictive pharmacology[2621].

5. Applications in Drug Discovery and Preclinical Testing

By offering predictive, patient-specific simulations that can expedite the development pipeline and lessen dependency on conventional experimental models, digital twin (DT) technology offers revolutionary applications in preclinical testing and drug discovery.

4.1 Lead optimization and virtual screening

Before chemical synthesis, researchers can forecast binding affinities, effectiveness, and possible off-target consequences thanks to DTs, which allow in silico simulation of receptor–ligand interactions under physiologically realistic conditions[12]. In the early phases of drug development, DTs save time and money by combining structural, molecular, and cellular data to optimize molecular characteristics, speed up lead discovery, and enable high-throughput virtual screening[34171827].

4.2 Modeling PK/PD

Pharmacokinetics (PK) and pharmacodynamics (PD) can be advancedly simulated across virtual patient populations using digital twins. Drug-drug interactions can be predicted, inter-individual variability can be identified, and exact dose optimization is made possible by DTs' modeling of absorption, distribution, metabolism, and excretion (ADME) profiles[2621]. When incorporated into DTs, physiologically based pharmacokinetic (PBPK) models offer a mechanistic comprehension of drug behavior at the organ and systemic levels, facilitating safer and more efficient preclinical evaluation[2621].

4.3 Predicting Toxicity

Prior to clinical trials, organ-specific toxicity, including hepatotoxicity and nephrotoxicity, can be predicted in silico using organ-specific digital twins, such as liver or kidney models[5]. In line with the 3Rs (replacement, reduction, refinement) in preclinical research, this predictive ability lessens reliance on animal models, promotes safer candidate selection, and makes early identification of negative effects easier[15].

4.4 Personalized medicine and clinical translation

Individualized therapeutic responses can be replicated by patient-specific DTs, allowing for customized dosage schedules and flexible therapy approaches. [6]. Wearable technology and IoMT integration enable continuous real-time monitoring, enabling feedback-based therapeutic modifications that support precision medicine and better clinical results[16]. Virtual clinical trials and customized medication development are made possible by these apps, which close the gap between preclinical testing and clinical practice[2621].

Table.3 Drug Discovery Stage in Digital Twin Application

		Digital Twin Application	
		DT Function and Benefit	**Relevant Section**
	Early Discovery	Virtual Screening & Lead Optimization	Enables in silico simulation of receptor–ligand interactions to predict binding affinity and optimize molecular properties, reducing cost and time.
	Preclinical Development	PK/PD Modeling	Simulates Pharmacokinetics (PK) and Pharmacodynamics (PD) using integrated PBPK models to achieve precise dose optimization and identify inter-individual variability.
	Preclinical Testing	Toxicity Prediction	Utilizes Organ-specific digital twins (e.g., liver, kidney) to predict organ-specific toxicity (in silico), facilitating safer candidate selection and supporting the 3Rs.
Drug Discovery Stage	**Clinical Translation**	Personalized Medicine & Virtual Clinical Trials	Patient-specific DTs simulate individualized therapeutic responses and enable adaptive treatment strategies. This bridges the gap to clinical practice and paves the way for virtual trials.

5. Advantages and Challenges

While digital twin (DT) technology has many benefits for preclinical testing and drug discovery, there are also major obstacles that need to be overcome before it can be widely used.

5.1 Benefits

Because virtual simulations can either replace or supplement resource-intensive animal research and early-phase human trials, one of the main advantages of DTs is the decrease in preclinical and clinical trial costs[12]. By including multi-scale physiological data and continuously updating the virtual system with real-world knowledge, DTs also offer higher predictive accuracy than conventional in vitro and in vivo models[34171827]. Additionally, by enabling patient-specific simulations to optimize dosage schedules, anticipate side effects, and customize treatment plans, DTs enable personalized therapeutic interventions and help to further the objectives of precision medicine[2621].

5.2 Difficulties

Notwithstanding these benefits, a number of obstacles prevent digital twins from being fully used in drug research. Robust infrastructure and advanced algorithms are necessary to enable accurate and timely simulations due to high computing load and data heterogeneity[34171827]. Regulatory bodies' approval of DT models is restricted by the absence of established validation procedures, which also makes benchmarking against traditional preclinical methodologies more difficult. The incorporation of patient-specific data into virtual models raises ethical questions about data privacy, security, and ownership[5789]. Furthermore, there is still regulatory ambiguity surrounding the use of model-based evidence in medication approval procedures, which calls for precise standards for clinical translation, repeatability, and validation[89].

Leveraging the full potential of DTs in drug development will require addressing these issues through ethical frameworks, regulatory harmonization, and technological innovation.

6. Ethical and Regulatory Perspectives

To ensure responsible use, a number of ethical and regulatory issues are brought up by the use of digital twin (DT) technology in personalized medicine and drug discovery. Since DTs depend on the integration of sensitive clinical, genetic, and real-time monitoring data, patient permission and data security are crucial[5789]. Patient privacy may be jeopardized by unauthorized access or exploitation of such data, hence strong cybersecurity safeguards and explicit informed consent procedures are required[5789].

Algorithmic bias presents another ethical dilemma. Unfair predictions or treatment recommendations may result from AI models employed in DTs inadvertently reflecting biases found in training datasets[34171827]. To reduce bias, foster stakeholder trust, and guarantee that forecasts are understandable and justified, transparent AI frameworks and explainable models are essential[34171827].

Table.4 Major obstacles hindering the widespread implementation of Digital Twins (DTs) in the pharmaceutical pipeline

Barrier Category	Specific Challenge	Description/Impact
Technical/Data	High Computational Demand and Data Heterogeneity	Requires robust infrastructure and sophisticated algorithms for accurate and timely simulations of diverse multi-scale data.
Scientific/Validation	Lack of Standardized Validation Frameworks	Limits regulatory acceptance and complicates benchmarking against conventional preclinical methods.
Ethical/Legal	Data Privacy, Security, and Ownership	Integration of sensitive patient-specific information requires robust cybersecurity and clear informed consent protocols.
Regulatory/Trust	Regulatory Uncertainty and Algorithmic Bias	Lack of clear guidelines for the acceptance of in silico evidence in drug approval and the risk of bias in AI models used in DTs.

Standards for the validation and acceptance of in silico evidence, including DT-based simulations, in preclinical and clinical decision-making are being investigated by regulatory bodies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)[89]. Prior to influencing regulatory approvals, these rules are intended to guarantee that model-based forecasts satisfy strict safety and scientific standards[89]

International projects like the Virtual Physiological Human (VPH) Project encourage computational model standardization and interoperability by offering structures for data integration, reproducibility, and cooperative study. For the safe, efficient, and fair use of digital twins in drug discovery and precision medicine, it will be crucial to harmonize ethical norms, legal requirements, and technical specifications[5789].

7. Future Perspectives

Advances in data integration, computational modeling, and safe information management are expected to determine the future of digital twin (DT) technologies in preclinical testing and drug discovery[34171827]. The incorporation of multi-omics data, such as transcriptomics, proteomics, metabolomics, and genomes, into AI-driven predictive models is a significant advancement that can improve the precision of individual-level therapy response predictions and disease simulations[12].

Another frontier is the creation of real-time adaptive digital twins, which are made possible by wearable technology and biosensors that continuously track physiological parameters[16]. Based on real-time patient data, these adaptive DTs can dynamically update virtual models, enabling more accurate dosage optimization, early adverse effect detection, and customized therapeutic modifications[2621].

DTs can be used in conjunction with blockchain technology to alleviate privacy and data security issues by offering a decentralized, impenetrable platform for exchanging biological data[23]. This facilitates cross-institutional collaborative research while guaranteeing transparency, traceability, and trust[5789].

A fully virtual clinical trial ecosystem, where patient-specific digital twins replicate drug efficacy, safety, and pharmacokinetics across various virtual populations, is the ultimate goal for DTs in the future[2621]. A paradigm change in personalized medicine and regulatory science could result from such a platform, which could improve predictive accuracy, speed up research timeframes, lower costs, and supplement traditional trials[2621].

These developments underscore the necessity of ongoing interdisciplinary cooperation, standardization, and ethical supervision while showcasing the revolutionary potential of DTs to reshape drug discovery, preclinical testing, and clinical translation[5789].

8. Conclusion

By making it possible to create "virtual humans" that faithfully replicate physiological, pathological, and therapeutic responses, digital twin (DT) technology is revolutionizing drug discovery and preclinical testing. DTs provide a predictive platform that can enhance preclinical evaluation's efficacy, cost-effectiveness, and ethical standards while lowering dependency on animal models by combining computer modeling, systems pharmacology, and artificial intelligence.

However, a number of crucial elements must come together for DTs to be successfully incorporated into standard pharmaceutical pipelines. For model-based forecasts to be dependable and scientifically sound, regulatory approval and the development of transparent validation mechanisms are necessary. To support repeatability and cooperative research, data formats and modeling platform interoperability must be standardized. Furthermore, to safeguard patient privacy and stop the exploitation of sensitive biomedical information, strong data governance and ethical monitoring must be put in place.

In the future, achieving the full potential of DTs will require sustained interdisciplinary cooperation between computer scientists, pharmacologists, doctors, and regulatory bodies. Digital twins are anticipated to be crucial to virtual clinical trials, customized medicine, and precision pharmacology as the technology advances, ultimately speeding up drug development and enhancing patient outcomes.

References

1. Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: applications to targets and beyond. *Br J Pharmacol.* 2007;152(1):21–37.
2. Viceconti M, Henney A, Morley-Fletcher E. In silico clinical trials: How computer simulation will transform the biomedical industry. *Int J Clin Trials128 Comput Biol Med.* 2016;57:1–10.
3. Laleh N, Manca D, Bertok B, Zio E. Digital twin for cyber-physical systems in medicine: A review. *Comput Chem Eng.* 2022;157:107585.
4. Zhao J, Ma H, Liu S, Zhang J. Digital twins and artificial intelligence in pharmaceutical research and development: A systematic review. *Drug Discov Today.* 2023;28(4):103692.
5. Bruynseels K, Santoni de Sio F, van den Hoven J. Digital twins in health care: Ethical implications of an emerging engineering paradigm. *Front Genet.* 2018;9:31.
6. Björnsson B, Borrebaeck C, Elander N, Gasslander T, Gawel DR, Gustafsson M, et al. Digital twins to personalize medicine. *Genome Med.* 2020;12(1):4.
7. Thomas RS, Bahadori T, Buckley TJ, Cowan-Ellsberry C, Dearman RJ, Hubal EAC, et al. The next generation blueprint of computational toxicology at the U.S. Environmental Protection Agency. *Toxicol Sci.* 2018;163(1):3–24.
8. European Medicines Agency (EMA). *Reflection paper on the use of AI in the medicinal product lifecycle.* London: EMA; 2023.
9. Food and Drug Administration (FDA). *Good Machine Learning Practice for Medical Device Development: Guiding Principles.* Silver Spring (MD): FDA; 2021.
10. Vassilev V, Gal C, Della Gatta F, Gherardini M, Viceconti M. The VPH framework for predictive systems medicine. *J Comput Sci.* 2020;46:101225.
11. Longo DL, Drazen JM. Data sharing. *N Engl J Med.* 2016;374(3):276–7.
12. Tao F, Zhang H, Liu A, Nee AYC. Digital twin in industry: State-of-the-art. *IEEE Trans Ind Inform.* 2019;15(4):2405–15.
13. Kassebaum NJ, et al. Global burden of disease attributable to diabetes and obesity: Global, regional, and national estimates. *Lancet.* 2020;396(10267):1223–34.
14. Herrero P, Georgiou P, Oliver N. A review of predictive mathematical models for the glucose–insulin system. *Proc IEEE.* 2018;106(4):701–16.
15. Bate A, Lindquist M, Edwards IR. A Bayesian neural network method for adverse drug reaction signal generation. *Eur J Clin Pharmacol.* 1998;54(4):315–21.
16. Li X, Dunn J, Salins D, Zhou G, Zhou W, Schüssler-Fiorenza Rose SM, et al. Digital health: Tracking physiomes and activity using wearable biosensors. *NPJ Digit Med.* 2017;1:18.
17. Kaul V, Enslin S, Gross SA. History of artificial intelligence in medicine. *Gastrointest Endosc.* 2020;92(4):807–12.

18. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. *Nat Med.* 2019;25(1):44–56.

19. Reddy AS, Zhang S. Polypharmacology: Drug discovery for the future. *Expert Rev Clin Pharmacol.* 2013;6(1):41–7.

20. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. The FAIR Guiding Principles for scientific data management and stewardship. *Sci Data.* 2016;3:160018.

21. Ballarin V, Smith J, Zhao L. Digital twin-based pharmacokinetic modeling for personalized drug therapy. *Pharmaceutics.* 2022;14(8):1662.

22. Sriram K, Insel PA. Digital twins for understanding and treating human disease. *Nat Rev Drug Discov.* 2018;17(8):531–2.

23. Esposito C, De Santis A, Tortora G, Chang H. Blockchain-based digital twin framework for healthcare. *IEEE Trans Ind Inform.* 2021;17(3):1966–75.

24. Kamel Boulos MN, Zhang P. Digital twins: From personalized medicine to precision public health. *J Pers Med.* 2021;11(8):745.

25. Glaessgen E, Stargel D. The digital twin paradigm for future NASA and US Air Force vehicles. *51st AIAA/ASME/ASCE/AHS/ASC Structures, Structural Dynamics, and Materials Conference.* 2010;1–14.

26. Herrmann M, et al. Digital twins for personalized healthcare: A perspective on system architecture. *IEEE Open J Eng Med Biol.* 2022;3:32–45.

27. Li R, Zhao J, Xu W. Artificial intelligence and digital twin integration in pharmaceutical development: Opportunities and challenges. *Comput Biol Med.* 2024;169:107764.

28. Viceconti M, Clapworthy G, Van Sint Jan S. The virtual physiological human – a European initiative for in silico human modeling. *J Physiol Sci.* 2008;58(7):441–6.

29. Tolk A, Diallo SY. Engineering principles of digital twins: A multidisciplinary approach. *J Comput Sci Eng.* 2018;14(2):103–15.

30. Zhang H, Tao F. An overview of digital twin development for healthcare applications. *IEEE Rev Biomed Eng.* 2023;16:1–16.